The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Uterine Fibroid Embolization Device Market In 2026 And 2030?
The market size for uterine fibroid embolization devices has experienced consistent growth over recent years. This market is projected to expand from $5.93 billion in 2025 to $6.19 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.4%. Historically, this expansion has been driven by several factors, including the increasing occurrence of uterine fibroids in women of reproductive age, a rise in gynecological procedures performed in hospitals and clinics, the enhanced adoption of uterine artery embolization within interventional radiology, greater knowledge of treatments that offer alternatives to open surgical myomectomy, and the broader implementation of minimally invasive treatment protocols in tertiary care facilities.
The market for uterine fibroid embolization devices is anticipated to experience consistent expansion over the upcoming years. This market is projected to reach $7.33 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. The anticipated growth during this period stems from several factors, including an increased need for uterus-sparing fibroid solutions, particularly among younger patients, a growing medical preference for non-invasive and minimally invasive treatments, greater implementation of procedures in ambulatory surgical centers, the expanded application of ablation and embolization devices for reducing fibroid dimensions, and heightened investments in sophisticated delivery catheters and embolic systems aimed at enhancing treatment accuracy. Key developments expected in the forecast period encompass a surge in the adoption of minimally invasive embolization methods for addressing uterine fibroids, a rising clinical inclination towards alternatives to hysterectomy that preserve organs, increased deployment of image-guided interventional devices for precise fibroid therapy, the broadening application of embolization procedures in outpatient and ambulatory settings, and an escalating requirement for accurate delivery systems to boost procedural safety and effectiveness.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Strong Drivers Are Impacting The Uterine Fibroid Embolization Device Market Growth?
The increasing demand for minimally invasive surgeries is anticipated to propel the expansion of the uterine fibroid embolization device market moving forward. Minimally invasive surgeries represent surgical approaches that utilize small incisions or natural bodily openings to reach and address internal structures, organs, or tissues, thereby minimizing patient trauma. The appetite for minimally invasive procedures is on the rise as more patients and healthcare providers favor treatments that reduce recuperation time, lower potential complication risks, and improve general comfort. Uterine fibroid embolization devices support these procedures by facilitating precise and effective treatment of fibroids, which in turn enhances patient outcomes and procedural efficiency. For instance, in January 2025, according to AOS Open, a US-based medical journal, the prevalence of minimally invasive surgeries in hospitals equipped with robotic-assisted systems increased to 65.8% in 2025, marking a rise from 60.5% in 2022. Consequently, the growing demand for minimally invasive surgeries is a primary driver for the growth of the uterine fibroid embolization device market.
Which Segment Classifications Are Used In The Uterine Fibroid Embolization Device Market Segment Analysis?
The uterine fibroid embolization device market covered in this report is segmented –
1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques
2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment
3) By End User: Hospitals, Clinics, Ambulatory Surgical Center
Subsegments:
1) By Surgical Techniques: Open Surgery, Myomectomy
2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy
3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation
4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)
Which Trends Are Contributing To Changes In The Uterine Fibroid Embolization Device Market?
Leading companies within the uterine fibroid embolization device market are developing innovative products, such as Minimally invasive fibroid management software, to enhance the precision and efficiency of uterine fibroid treatment. This Minimally invasive fibroid management software represents an advanced digital platform designed to assist clinicians in the planning, guidance, and execution of minimally invasive procedures for treating uterine fibroids, thereby improving procedural precision, safety, and overall patient outcomes. For instance, in September 2024, Gynesonics, a US-based medical device company specializing in minimally invasive gynecologic treatments, launched SMART OS 2.4 software for the Sonata System to enhance the management of uterine fibroids. SMART OS 2.4 improves the proprietary SMART Guide by reducing the minimum ablation zone size from 2.0 × 1.3 cm to 1.6 × 1.2 cm, decreasing ablation volume by 38%, and optimizing the Thermal Safety Border for smaller fibroids. These enhancements allow for more precise, controlled treatments while preserving healthy uterine tissue, improving both procedural efficiency and patient outcomes.
Which Firms Are Contributing To The Uterine Fibroid Embolization Device Market Ecosystem?
Major companies operating in the uterine fibroid embolization device market are Johnson and Johnson Pvt Ltd., Medtronic plc., Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, Ethicon Inc., Hologic Inc., CooperSurgical Inc., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., Hironic Co.Ltd, Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC
Get The Full Uterine Fibroid Embolization Device Market Report:
Which Region Is The Largest In The Uterine Fibroid Embolization Device Market?
North America was the largest region in the uterine fibroid embolization device market in 2025. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Uterine Fibroid Embolization Device Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Uterine Fibroid Embolization Device Market 2026, By The Business Research Company
Uterine Fibroids Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report
Uterine Fibroids Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report
Tumor Embolization Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model